TY  - JOUR

T1  - A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.

JO  - Journal of Clinical Oncology

PY  - 2022/02/20

AU  - Crabb SJ

AU  - Hussain SA

AU  - Soulis E

AU  - Hinsley S

AU  - Dempsey L

AU  - Trevethan A

AU  - Song YP

AU  - Barber J

AU  - Frew JA

AU  - Gale J

AU  - Faust G et al

ED  - 

DO  - DOI: 10.1200/jco.2022.40.6_suppl.436

PB  - American Society of Clinical Oncology (ASCO)

VL  - 40

IS  - 6_suppl

SP  - 436

EP  - 436

Y2  - 2024/12/21

ER  -